Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

TRIQ Searching for TRans-eQTL affecting the risk to develop Inflammatory Bowel Disease

Coordinator
Universite De Liege, Belgium
Runs
1 May 2024 to 30 April 2026
Status
Running
EU funding
€192k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101155061

What the project is doing

In the project's own words, from its summary on CORDIS.

Inflammatory Bowel Disease, including Crohn’s disease and ulcerative colitis, now afflict close to 1/250 individuals in industrialized societies. There is a pressing need for effective preventive means as well as curative drugs. Cis-eQTL analyses are uncovering a growing list of genes that are perturbed by IBD risk variants detected by GWAS, constituting a list of prime drug targets for the pharmaceutical industry. Cis-eQTL effects trigger downstream effects – both within the same (intracellular) and other cell types (intercellular) – that culminate in disease declaration.

Some of these downstream effects are accompanied by changes in transcript levels referred to as trans-eQTL effects. The aim of the TRIQ project is to take advantage of the CEDAR-II dataset – transcriptome data for up to 400 individuals in > 75 IBD-relevant cell types – to identify trans-eQTL effects that mediate IBD predisposition. The genes that are perturbed by these trans-effect will include druggable targets that constitute prime targets for the development of new IBD therapies.

Topics

Who is involved

OrganisationCityCountryRole
Universite De LiegeLiegeBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI